Your email has been successfully added to our mailing list.

×
0.0537096774193549 0.129032258064516 0.123655913978495 0.075268817204301 0.0271505376344086 0.112903225806452 0.145161290322581 0.10752688172043
Stock impact report

NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV?G-ZEBOV-GP) to U.S. Food and Drug Administration

NEWLINK GENETICS (NLNK) 
Last newlink genetics earnings: 2/28 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.linkp.com/investor-relations
Company Research Source: GlobeNewswire
In 2014 the Company entered into a license agreement with Merck to develop, manufacture and commercialize NewLink Genetics’ Ebola vaccine candidate              AMES, Iowa, Nov. 15, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV?G-ZEBOV-GP, live attenuated).  This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016 and is anticipated to be completed in 2019. The FDA’s approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.  Thereafter, NewLink would have the right to monetize its share of interest in the voucher.  This Ebola vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC Show less Read more
Impact Snapshot
Event Time:
NLNK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NLNK alerts
Opt-in for
NLNK alerts

from News Quantified
Opt-in for
NLNK alerts

from News Quantified